Compare NetEase Inc (NTES) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? NetEase Inc trades at $115.64 (market cap $76.85B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and NetEase Inc pays a 2.45% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NTES | VRTX | |
|---|---|---|
Market Cap | $76.85B | $134.06B |
Sector | Media | Health |
52-Week High | $159.34 | $557.96 |
52-Week Low | $109.26 | $376.62 |
Enterprise Value | $52.59B | $128.18B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $119.45, up 0.13% on the day, with a bearish technical signal from moving averages and mixed earnings performance including a Q2 2026 EPS miss. The company maintains strong profitability with a 27.88% net income margin and robust cash flow, though net cash flow turned negative in 2025. Recent news highlights dividend growth and international expansion efforts amid competitive pressures.
The stock presents a valuation opportunity with a P/E of 15.93 below sector averages, supported by an 81.82% analyst buy rating. Key risks include earnings volatility and heavy investing outflows, but solid fundamentals and global growth initiatives offer long-term upside potential for patient investors.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
